{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:01:52Z","timestamp":1788303712751,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"am","delay-in-days":327,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21zf0127004"],"award-info":[{"award-number":["JP21zf0127004"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K20706"],"award-info":[{"award-number":["21K20706"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19H03593"],"award-info":[{"award-number":["19H03593"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.nucmedbio.2022.03.005","type":"journal-article","created":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T21:28:25Z","timestamp":1648157305000},"page":"85-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Reduction of tumor hypoxia by anti-PD-1 therapy assessed using pimonidazole and [18F]FMISO"],"prefix":"10.1016","volume":"108-109","author":[{"given":"Kohei","family":"Nakajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsunori","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motofumi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Yokouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Takakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikako","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0005","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1093\/jnci\/93.4.266","article-title":"Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects","volume":"93","author":"H\u00f6ckel","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0010","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc704","article-title":"Hypoxia - A key regulatory factor in tumour growth","volume":"2","author":"Harris","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0015","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10555-007-9055-1","article-title":"Hypoxia in cancer: significance and impact on clinical outcome","volume":"26","author":"Vaupel","year":"2007","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0020","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.addr.2016.10.002","article-title":"Molecular targeting of hypoxia in radiotherapy","volume":"109","author":"Rey","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0025","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jnci\/djm135","article-title":"Drug resistance and the solid tumor microenvironment","volume":"99","author":"Tr\u00e9dan","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/jitc-2020-002088","article-title":"Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck","volume":"9","author":"Zandberg","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0035","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1158\/0008-5472.CAN-13-0992","article-title":"A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells","volume":"74","author":"Barsoum","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0040","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced: MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0045","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.3390\/cells8091083","article-title":"Improving cancer immunotherapy by targeting the hypoxic tumor microenvironment: new opportunities and challenges","volume":"8","author":"Noman","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0050","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3390\/cells10051006","article-title":"Tumour hypoxia-mediated immunosuppression: mechanisms and therapeutic approaches to improve cancer immunotherapy","volume":"10","author":"Fu","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-021-02000-x","article-title":"Interfering with tumor hypoxia for radiotherapy optimization","volume":"40","author":"Telarovic","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0060","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/5721258","article-title":"Recent research on methods to improve tumor hypoxia environment","volume":"2020","author":"Zhu","year":"2020","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0065","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0070","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.apsb.2020.09.014","article-title":"Manipulation of immune\u2013vascular crosstalk: new strategies towards cancer treatment","volume":"10","author":"Zhao","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0075","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1172\/JCI96582","article-title":"Increased vessel perfusion predicts the efficacy of immune checkpoint blockade","volume":"128","author":"Zheng","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0080","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.nucmedbio.2005.03.010","article-title":"Fully automated one-pot synthesis of [18F]fluoromisonidazole","volume":"32","author":"Tang","year":"2005","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0085","doi-asserted-by":"crossref","DOI":"10.1038\/srep16802","article-title":"The accumulation mechanism of the hypoxia imaging probe \u201cFMISO\u201d by imaging mass spectrometry: possible involvement of low-molecular metabolites","volume":"5","author":"Masaki","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0090","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13550-018-0433-1","article-title":"Anti PD-1 treatment increases [18F]FDG uptake by cancer cells in a mouse B16F10 melanoma model","volume":"8","author":"Tomita","year":"2018","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0095","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13550-020-0608-4","article-title":"Influence on [18F] FDG uptake by cancer cells after anti-PD-1 therapy in an enforced- immune activated mouse tumor","volume":"10","author":"Tomita","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0100","first-page":"1","article-title":"Preclinical development of ipilimumab and nivolumab combination immunotherapy: Mouse tumor models, In vitro functional studies, and cynomolgus macaque toxicology","volume":"11","author":"Selby","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0105","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1158\/2326-6066.CIR-16-0114","article-title":"Rational selection of syngeneic preclinical tumor models for immunotherapeutic drug discovery","volume":"5","author":"SIS","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0110","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Sawada","year":"2005","journal-title":"Science (80-)"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0115","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd3455","article-title":"Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases","volume":"10","author":"Carmeliet","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13030499","article-title":"Tumor hypoxia as a barrier in cancer therapy: why levels matter","volume":"13","author":"Hompland","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0125","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/onc.2009.416","article-title":"Immune infiltration in human tumors: A prognostic factor that should not be ignored","volume":"29","author":"Pag\u00e8s","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0130","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1084\/jem.20160801","article-title":"PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity","volume":"214","author":"Juneja","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0135","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1158\/1078-0432.CCR-18-2407","article-title":"The effectiveness of checkpoint inhibitor combinations and administration timing can be measured by granzyme B PET imaging","volume":"25","author":"Larimer","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0140","doi-asserted-by":"crossref","first-page":"15408","DOI":"10.1073\/pnas.1512832112","article-title":"STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity","volume":"112","author":"Demaria","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nucmedbio.2022.03.005_bb0145","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1158\/1078-0432.CCR-21-2394","article-title":"18F-FMISO PET imaging identifies hypoxia and immunosuppressive tumor microenvironments and guides targeted evofosfamide therapy in tumors refractory to PD-1 and CTLA-4 inhibition","volume":"28","author":"Reeves","year":"2022","journal-title":"Clin Cancer Res"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805122000300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805122000300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T04:30:52Z","timestamp":1760848252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805122000300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":29,"alternative-id":["S0969805122000300"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2022.03.005","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction of tumor hypoxia by anti-PD-1 therapy assessed using pimonidazole and [18F]FMISO","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2022.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}